Adult Stem Cell Firm Receives Calif. Production License

StemCells, Inc. announced that it has received a manufacturing license for its cell processing facility from the State of California Department of Health Services, Food and Drug Branch. This enables the Company to use its proprietary neural cell therapy product, HuCNS-SC, which is made at its licensed facility, in clinical trials. In addition, the company believes this improves its position as a potential recipient of California Proposition 71 funds. StemCells has already filed an application with the US Food and Drug Administration to begin a clinical trial of a human neural stem cell treatment for Batten disease, a rare and fatal neurodegenerative genetic condition affecting infants and children. The trial is on clinical hold pending a complete response acceptable to the FDA.